Logo Phibro Animal Health

Phibro Animal Health (PAHC) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Phibro Animal Health · Health Care · ref. ETF XLV · 50 calls · price $36.35
🏆JPI 2026 portfoliosSee tracking →
What the company does: Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

📈 Phibro Animal Health (PAHC) stock price

$36.35-5.5% over range
Aug 28, 25low $28.52 · high $59.58Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
0% recommend buying · 1 analysts
📊 JPI status : Phibro Animal Health has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 PAHC price target & analyst consensusprice $36.35

The price target · all analysts combined (1 targets)
Highest target · 1 firm of 1$44+21.0%
Median target · of 1 targets$44+21.0%
Lowest target · 1 firm of 1$44+21.0%
Current price$36.35
⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

The consensus · 1 ratings (last 6 months)
Strong Buy00%
Buy00%
Hold1100%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Phibro Animal Health? The JPI assistant answers using our backtest data.

🏛️ Phibro Animal Health insider buying: who's buying and how much › open the full page

1 insider bought1 buys / 6 mo $318k

🔎 Detailed analyses

✅ Historical analyst reliability on PAHC

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
Roth MKM 100% +44.2% 2
Morgan Stanley  100% +33.7% 4
Barclays  58% -4.7% 12
Credit Suisse 50% +4.3% 2
B of A Securities  33% -4.7% 3

📊 What $1,000 invested in Phibro Animal Health would be worth › open the full page

In short — $1,000 invested in Phibro Animal Health 10 years ago would be worth $1,097 today, i.e. +1%/yr on average. Best year: 2024 (+81%), worst: 2022 (-34%). Price performance, excluding dividends.

If I'd invested $1,000 in Phibro Animal Health

InvestmentWorth todayGain
1 years ago$1,573+57%
3 years ago$2,464+146%
5 years ago$1,701+70%
→ See Phibro Animal Health's full return history + gain calculator

Return by year (Phibro Animal Health)

YearReturn$1,000 invested at year start
2026 (YTD)-12%$884 (-12%)
2025+78%$1,573 (+57%)
2024+81%$2,853 (+185%)
→ See Phibro Animal Health's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Phibro Animal Health

Loading news…

📋 All analyst calls on PAHC

Citigroup 
May 14, 26
■ Neutral neutral · not a buy · 🎯$44
Price at call : $34.37 — gap to target +28%
Today : $36.35 — gap to target +21%
🎯 on PAHC : no call matured yet · 📊 on Health : 43.8% · -5.4% (105 calls)
in progress (365j)
matures : May 14, 27
Citigroup 
Apr 15, 26
■ Neutral neutral · not a buy · 🎯$62
Price at call : $53.88 — gap to target +15%
Today : $36.35 — gap to target +71%
🎯 on PAHC : no call matured yet · 📊 on Health : 43.8% · -5.4% (105 calls)
in progress (365j)
matures : Apr 15, 27
JP Morgan 
Nov 7, 25
▲ Overweight · 🎯$50
Price at call : $45.83 — upside +9%
Today : $36.35 — upside +38%
🎯 on PAHC : 100% (1 call matured) · 📊 on Health : 49.3% · +6.9% (146 calls)
in progress (365j)
matures : Nov 7, 26
▼ Underperform · 🎯$27
Price at call : $36.69 — upside -26%
Today : $36.35 — upside -26%
🎯 on PAHC : 0% (2 calls matureds) · 📊 on Health : 51.3% · +3.0% (152 calls)
in progress (365j)
matures : Aug 29, 26
JP Morgan 
Jul 7, 25
▲ Overweight · 🎯$35
Price at call : $29.9 — upside +17%
Today : $36.35 — upside -4%
Expected +17% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on PAHC : 100% (1 call matured) · 📊 on Health : 49.3% · +6.9% (146 calls)
+10.8%
stock +11% · XLV +22%
matured Jul 7, 26
Morgan Stanley 
Jun 25, 25
■ Equal-Weight neutral · not a buy · 🎯$26
Price at call : $25.12 — gap to target +4%
Today : $36.35 — gap to target -28%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Jun 25, 26
■ Equal-Weight neutral · not a buy · 🎯$21
Price at call : $22.47 — gap to target -7%
Today : $36.35 — gap to target -42%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 8, 26
Barclays 
Feb 10, 25
▼ Underweight · 🎯$22
Price at call : $26.22 — upside -16%
Today : $36.35 — upside -39%
Expected -16% · Actual +97% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-97.3%
stock +97% · XLV +6%
matured Feb 10, 26
See the other 42 calls, newest to oldest
Morgan Stanley 
Dec 17, 24
■ Equal-Weight neutral · not a buy · 🎯$25
Price at call : $21.27 — gap to target +18%
Today : $36.35 — gap to target -31%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Dec 17, 25
Barclays 
Nov 12, 24
▼ Underweight · 🎯$20
Price at call : $25.27 — upside -21%
Today : $36.35 — upside -45%
Expected -21% · Actual +77% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-76.9%
stock +77% · XLV +4%
matured Nov 12, 25
JP Morgan 
Sep 10, 24
■ Neutral neutral · not a buy · 🎯$22
Price at call : $20.88 — gap to target +5%
Today : $36.35 — gap to target -39%
🎯 on PAHC : 100% (1 call matured) · 📊 on Health : 49.3% · +6.9% (146 calls)
in progress (365j)
matures : Sep 10, 25
▼ Underperform · 🎯$15
Price at call : $21 — upside -29%
Today : $36.35 — upside -59%
Expected -29% · Actual +75% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 0% (2 calls matureds) · 📊 on Health : 51.3% · +3.0% (152 calls)
-74.7%
stock +75% · XLV -12%
matured Aug 30, 25
Barclays 
May 10, 24
▼ Underweight · 🎯$13
Price at call : $18.11 — upside -28%
Today : $36.35 — upside -64%
Expected -28% · Actual +35% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-35.3%
stock +35% · XLV -5%
matured May 10, 25
■ Equal-Weight neutral · not a buy · 🎯$16
Price at call : $9.66 — gap to target +66%
Today : $36.35 — gap to target -56%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Nov 8, 24
Roth MKM
Sep 1, 23
▲ Buy · 🎯$21
Price at call : $13.43 — upside +56%
Today : $36.35 — upside -42%
Expected +56% · Actual +48% · Reason (≥ +15%) : ✓ Yes
🎯 on PAHC : 100% (2 calls matureds) · 📊 unranked overall
+47.9%
stock +48% · XLV +19%
matured Aug 31, 24
Morgan Stanley 
Aug 31, 23
■ Equal-Weight neutral · not a buy · 🎯$17
Price at call : $13.95 — gap to target +22%
Today : $36.35 — gap to target -53%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Aug 30, 24
Roth MKM
Aug 29, 23
▲ Buy · 🎯$21
Price at call : $14.81 — upside +42%
Today : $36.35 — upside -42%
Expected +42% · Actual +41% · Reason (≥ +15%) : ✓ Yes
🎯 on PAHC : 100% (2 calls matureds) · 📊 unranked overall
+40.5%
stock +41% · XLV +15%
matured Aug 28, 24
Morgan Stanley 
Jul 27, 23
■ Equal-Weight neutral · not a buy · 🎯$18
Price at call : $14.37 — gap to target +25%
Today : $36.35 — gap to target -50%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Jul 26, 24
■ Equal-Weight neutral · not a buy · 🎯$18
Price at call : $14.31 — gap to target +26%
Today : $36.35 — gap to target -50%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 3, 24
■ Equal-Weight neutral · not a buy · 🎯$19
Price at call : $15.9 — gap to target +19%
Today : $36.35 — gap to target -48%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Feb 9, 24
Roth Capital
Dec 21, 22
▲ Buy · 🎯$18
Price at call : $13.67 — upside +32%
Today : $36.35 — upside -50%
Expected +32% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on PAHC : 0% (1 call matured) · 📊 unranked overall
-16.7%
stock -17% · XLV -1%
matured Dec 21, 23
Morgan Stanley 
Nov 10, 22
■ Equal-Weight neutral · not a buy · 🎯$20
Price at call : $13.98 — gap to target +43%
Today : $36.35 — gap to target -45%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Nov 10, 23
Barclays 
Sep 16, 22
▼ Underweight · 🎯$17
Price at call : $14.47 — upside +17%
Today : $36.35 — upside -53%
Expected +17% · Actual -13% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
+13.3%
stock -13% · XLV +3%
matured Sep 16, 23
Morgan Stanley 
Aug 26, 22
■ Equal-Weight neutral · not a buy · 🎯$21
Price at call : $15.99 — gap to target +31%
Today : $36.35 — gap to target -42%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Aug 26, 23
Barclays 
Jul 25, 22
▼ Underweight · 🎯$22
Price at call : $18.82 — upside +17%
Today : $36.35 — upside -39%
Expected +17% · Actual -22% · Reason (≤ −15%) : ✓ Yes
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
+22.4%
stock -22% · XLV +4%
matured Jul 25, 23
Barclays 
Jan 10, 22
■ Equal-Weight neutral · not a buy · 🎯$23
Price at call : $21.27 — gap to target +8%
Today : $36.35 — gap to target -37%
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Jan 10, 23
Morgan Stanley 
Nov 18, 21
■ Equal-Weight neutral · not a buy · 🎯$23
Price at call : $21.79 — gap to target +6%
Today : $36.35 — gap to target -37%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Nov 18, 22
Barclays 
Jul 7, 21
▼ Underweight · 🎯$23
Price at call : $26.77 — upside -14%
Today : $36.35 — upside -37%
Expected -14% · Actual -27% · Reason (≤ −15%) : ✓ Yes
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
+26.5%
stock -27% · XLV +1%
matured Jul 7, 22
Morgan Stanley 
May 13, 21
▼ Underweight · 🎯$22
Price at call : $27.52 — upside -20%
Today : $36.35 — upside -39%
Expected -20% · Actual -33% · Reason (≤ −15%) : ✓ Yes
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+32.7%
stock -33% · XLV +5%
matured May 13, 22
Credit Suisse
May 8, 20
■ Neutral neutral · not a buy · 🎯$23
Price at call : $22.76 — gap to target +1%
Today : $36.35 — gap to target -37%
🎯 on PAHC : 50% (2 calls matureds) · 📊 unranked overall
in progress (365j)
matures : May 8, 21
Gabelli & Co.
Feb 6, 20
■ Hold neutral · not a buy
🎯 on PAHC : 0% (1 call matured) · 📊 unranked overall
in progress (365j)
matures : Feb 5, 21
Barclays 
Jan 28, 20
■ Equal-Weight neutral · not a buy · 🎯$23
Price at call : $26 — gap to target -12%
Today : $36.35 — gap to target -37%
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Jan 27, 21
■ Equal-Weight neutral · not a buy · 🎯$21
Price at call : $21.28 — gap to target -1%
Today : $36.35 — gap to target -42%
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Sep 4, 20
▼ Underperform · 🎯$18
Price at call : $21.14 — upside -15%
Today : $36.35 — upside -50%
Expected -15% · Actual +2% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 0% (2 calls matureds) · 📊 on Health : 51.3% · +3.0% (152 calls)
-2.1%
stock +2% · XLV +19%
matured Aug 28, 20
Barclays 
Aug 29, 19
▼ Underweight · 🎯$18
Price at call : $21.14 — upside -15%
Today : $36.35 — upside -50%
Expected -15% · Actual +2% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-2.1%
stock +2% · XLV +19%
matured Aug 28, 20
Credit Suisse
Aug 28, 19
■ Neutral neutral · not a buy · 🎯$25
Price at call : $21.74 — gap to target +15%
Today : $36.35 — gap to target -31%
🎯 on PAHC : 50% (2 calls matureds) · 📊 unranked overall
in progress (365j)
matures : Aug 27, 20
Barclays 
Jun 11, 19
▼ Underweight · 🎯$25
Price at call : $28.03 — upside -11%
Today : $36.35 — upside -31%
Expected -11% · Actual -4% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
+3.6%
stock -4% · XLV +13%
matured Jun 10, 20
Gabelli & Co.
May 9, 19
▲ Buy
Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on PAHC : 0% (1 call matured) · 📊 unranked overall
-27.4%
stock -27% · XLV +12%
matured May 8, 20
Morgan Stanley 
Aug 29, 18
▼ Underweight · 🎯$46
Price at call : $47 — upside -2%
Today : $36.35 — upside +27%
Expected -2% · Actual -55% · Reason (≤ −15%) : ✓ Yes
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+55.0%
stock -55% · XLV -3%
matured Aug 29, 19
Barclays 
Jul 5, 18
▼ Underweight · 🎯$33
Price at call : $47.15 — upside -30%
Today : $36.35 — upside -9%
Expected -30% · Actual -31% · Reason (≤ −15%) : ✓ Yes
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
+31.4%
stock -31% · XLV +11%
matured Jul 5, 19
Credit Suisse
May 9, 18
■ Neutral neutral · not a buy · 🎯$42
Price at call : $43.95 — gap to target -4%
Today : $36.35 — gap to target +16%
🎯 on PAHC : 50% (2 calls matureds) · 📊 unranked overall
in progress (365j)
matures : May 9, 19
▼ Underweight · 🎯$36
Price at call : $36.6 — upside -2%
Today : $36.35 — upside -1%
Expected -2% · Actual -16% · Reason (≤ −15%) : ✓ Yes
🎯 on PAHC : 100% (3 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+16.4%
stock -16% · XLV +7%
matured Feb 7, 19
Credit Suisse
Feb 6, 18
■ Neutral neutral · not a buy · 🎯$39
Price at call : $36.6 — gap to target +7%
Today : $36.35 — gap to target +7%
🎯 on PAHC : 50% (2 calls matureds) · 📊 unranked overall
in progress (365j)
matures : Feb 6, 19
Credit Suisse
Aug 31, 17
▲ Outperform · 🎯$37
Price at call : $36.5 — upside +1%
Today : $36.35 — upside +2%
Expected +1% · Actual +31% · Reason (≥ +15%) : ✓ Yes
🎯 on PAHC : 50% (2 calls matureds) · 📊 unranked overall
+30.7%
stock +31% · XLV +13%
matured Aug 31, 18
Piper Sandler 
Dec 15, 16
▲ Overweight · 🎯$32
Price at call : $28.05 — upside +14%
Today : $36.35 — upside -12%
Expected +14% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on PAHC : 100% (1 call matured) · 📊 on Health : 45.8% · +6.9% (249 calls)
+18.9%
stock +19% · XLV +20%
matured Dec 15, 17
Macquarie 
Nov 11, 16
▼ Underperform
Actual +20% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 0% (1 call matured) · 📊 on Health : 40% · +4.7% (10 calls)
-20.0%
stock +20% · XLV +15%
matured Nov 11, 17
Gabelli & Co.
Nov 10, 16
■ Hold neutral · not a buy
🎯 on PAHC : 0% (1 call matured) · 📊 unranked overall
in progress (365j)
matures : Nov 10, 17
Macquarie 
Feb 17, 16
■ Neutral neutral · not a buy · 🎯$35
Price at call : $28.34 — gap to target +24%
Today : $36.35 — gap to target -4%
🎯 on PAHC : 0% (1 call matured) · 📊 on Health : 40% · +4.7% (10 calls)
in progress (365j)
matures : Feb 16, 17
Credit Suisse
Feb 3, 16
▲ Outperform · 🎯$42
Price at call : $34.87 — upside +20%
Today : $36.35 — upside +16%
Expected +20% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on PAHC : 50% (2 calls matureds) · 📊 unranked overall
-22.0%
stock -22% · XLV +9%
matured Feb 2, 17
Barclays 
Jan 15, 16
▼ Underweight · 🎯$31
Price at call : $28.77 — upside +8%
Today : $36.35 — upside -15%
Expected +8% · Actual -4% · Reason (≤ −15%) : ✗ No
🎯 on PAHC : 60% (10 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
+3.5%
stock -4% · XLV +6%
matured Jan 14, 17

Frequently asked questions

Should I buy Phibro Animal Health stock?

This isn't buy advice. For Phibro Animal Health, the analyst consensus is "Hold", with an average price target of $44.00 (+21% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Phibro Animal Health). We show the numbers — you decide.

Is it too late to buy Phibro Animal Health? How high can it go?

The most bullish analyst target on Phibro Animal Health is $44.00 (+21% above today's price); the average is $44.00. That's the upside they see. Check how reliable those analysts have actually been on Phibro Animal Health on our site before trusting it.

Is Phibro Animal Health still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 5 analysts have a real record on Phibro Animal Health, the best hitting 100% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.

Will Phibro Animal Health stock recover (go back up)?

It's down from its high. We answer with the numbers — the analysts' 12-month target and what happened after its past drops: will PAHC stock recover (go back up)?

What has Phibro Animal Health's past performance been?

Historical returns and a "how much if I had invested" calculator: PAHC performance & returns.

Are insiders buying PAHC stock?

Executives' and large holders' buys and sells, decoded: insider buying on PAHC.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)